Infusion seat, infusion device, and related method
By setting up a filter in the fluid transport component of the infusion device, unwanted substances are removed, the problems of inflammation and fibrosis reactions at the infusion site are solved, the use time of the insulin pump is extended, and the treatment effect is improved.
Patent Information
- Application Number
- CN202380032815.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-07
- Filing Date
- 2023-04-05
- Publication Date
- 2024-11-22
AI Technical Summary
The existing continuous subcutaneous insulin infusion devices can easily lead to inflammation and fibrosis reactions at the infusion site during use, resulting in accelerated wear of the device, affecting the treatment effect and use time.
An infusion base with a filter is designed to remove unwanted substances by installing physical or chemical filter media in the fluid transport component to reduce immune responses, thereby inhibiting inflammation and fibrosis reactions and prolonging the use of infusion devices. time.
It effectively inhibits the inflammation and fibrosis reactions at the infusion site, extends the use time of the insulin pump, and can be at least four days, reducing the impact on the patient's discomfort and treatment effect.
Smart Images

Figure CN119013074A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an infusion seat and an infusion device / infusion set for subcutaneously infusing a therapeutic agent into a patient and related methods. In particular (but not exclusively), the present invention relates to an infusion device for subcutaneously infusing insulin, heparin, apomorphine, arbidopa or levodopa and / or levodopa products into a patient. Background Art
[0002] For people with diabetes, insulin therapy is often an important part of their treatment, helping to regulate blood sugar levels and store excess glucose for energy. There are two main modes of insulin delivery. The first mode includes syringes and pen injectors, which are used to inject a set dose of insulin, usually three to four times a day (depending particularly on the type of diabetes and the patient's blood sugar levels). While these devices are simple and low cost, delivering each dose of insulin requires a needle stick. The second mode uses an infusion pump, sometimes called an insulin pump, which delivers controlled doses of insulin throughout the day. Infusion pumps can be used to deliver insulin to patients continuously (basal dosing), on demand (single dose), or at predetermined intervals. Infusion pumps are more complex and more expensive than syringes and pens, but can improve the regulation of blood sugar levels, for example through programmable delivery schedules, and require fewer needle sticks.
[0003] The second mode is called continuous subcutaneous insulin infusion (CSII) therapy. The infusion pump system for CSII treatment can be worn by the patient. The system generally includes a combined infusion pump and a reservoir for accommodating insulin drugs (such as human insulin or simulated insulin), and an insulin infusion device. The infusion device can include a cannula / cannula (such as a polymer catheter or a metal needle) for inserting the patient's subcutaneous and a flexible pipeline for connecting the cannula fluid to the reservoir. Once the cannula is inserted into the patient's body, it can remain in place for a period of time, i.e., a few days, to allow continuous delivery of insulin drugs. The use time of the insulin infusion device currently recommended is two to three days, to avoid possible problems related to the infusion device itself or the infusion site. However, within the recommended wearing time, these problems will still occur, causing the premature removal of the infusion device and more frequent position rotation between the infusion sites (such as buttocks, abdomen and arms).
[0004] While infusion set-related problems have been well investigated and addressed in recent years, there is still a lack of understanding and solutions to address infusion site-related problems. Infusion site-related problems include pain, bleeding, infection, skin irritation, erythema, lipohypertrophy, and lipoatrophy. Infusion site problems can lead to the formation of scar tissue, which can reduce insulin sensitivity, increase the risk of hypoglycemia, and have an impact on the patient's appearance. All of these issues can discourage patients from continuing to use their infusion pumps, leading to poor patient outcomes.
[0005] It is well known that infusion site problems are the result of immune responses to cannulas and insulin medications in the body. The immune system responds by activating and promoting a foreign body reaction (FBR), an inflammatory and fibrotic process that occurs when foreign material is introduced into the body. In the FBR, cells of the immune system recognize foreign material (e.g., unwanted biological, chemical, or physical species present in an infusible solution) and attempt to degrade it or to enclose the material by forming a physical barrier to isolate it from the rest of the body. FBR is a problem in CSII therapy that increases wear time on the infusion set as the immune system responds to the inserted cannulas and insulin medications. This limitation prevents the full potential of CSII therapy from being realized.
[0006] Often, the presence of harmful substances in insoluble solutions—whether biological, chemical, or physical—can result in adverse consequences for the patient.
[0007] It is an object of embodiments of the present invention to provide an improved infusion device that seeks to avoid FBR, increase the wearing time of the infusion device, and / or at least alleviate one or more problems associated with known devices. Summary of the invention
[0008] The invention is defined by the appended claims.
[0009] The present disclosure provides an infusion seat for subcutaneously infusing a therapeutic agent into a patient, the infusion seat comprising: a housing; a cannula for insertion into the patient's body; a fluid transfer component connected to the housing and in fluid communication with the cannula; and a tubing connector configured to engage the fluid transfer component and connect to a tubing for receiving the therapeutic agent from a pump; wherein the cannula defines a downstream end of a fluid flow path extending between the pump and the patient via the fluid transfer component; and wherein the infusion seat comprises a filter disposed in the tubing connector.
[0010] The present disclosure also provides a method for treating a patient by subcutaneous infusion of a therapeutic agent, the method comprising the following steps: placing the infusion seat described herein at an infusion site of the patient, connecting a pump connected to a source fluid of the therapeutic agent to a tubing connector via a tubing, priming the tubing with the therapeutic agent, and injecting / infusing the patient with the therapeutic agent.
[0011] The present disclosure also provides a method for treating a patient by subcutaneously infusing a therapeutic agent, the method comprising the following steps: providing an infusion seat as described herein, connecting a pump connected to a source of therapeutic agent fluid to a tubing connector via a tubing, priming the tubing with the therapeutic agent, placing the infusion seat at an infusion site of the patient, and injecting the therapeutic agent into the patient. Connecting tubing between the tubing connector of the infusion seat and the pump; inserting a cannula into the patient; and introducing the therapeutic agent into the patient.
[0012] The present disclosure also provides an infusion seat for subcutaneously infusing a therapeutic agent into a patient, the infusion seat comprising: a housing; a cannula for insertion into the patient's body; a fluid transfer component connected to the housing and in fluid communication with the cannula; and a tubing connector configured to engage the fluid transfer component and connect to a tubing for receiving the therapeutic agent from a pump; wherein the cannula defines a downstream end of a fluid flow path extending between the pump and the patient via the fluid transfer component; and wherein the infusion seat comprises a filter disposed within the fluid transfer component in the fluid flow path.
[0013] The present disclosure also provides an infusion device, comprising: the infusion seat described herein; and a pipeline connectable between a pipeline connector of the infusion seat and a pump.
[0014] In some cases, the infusion set further includes a pump for containing the therapeutic agent and delivering the therapeutic agent to the infusion set via the tubing.
[0015] In some cases, the interface of the fluid transport component includes a sealing membrane for preventing fluid from flowing out of the fluid transport component from the fluid flow path.
[0016] In some cases, when the tubing connector is secured to the fluid transport component, the needle of the tubing connector may pierce the sealing membrane of the fluid transport component.
[0017] In some cases, the pipe connection includes an upstream fluid lumen, a downstream fluid lumen, and a cavity disposed between the upstream fluid lumen and the downstream fluid lumen; wherein the filter is disposed in the cavity in the fluid flow path.
[0018] In some cases, a filter is disposed in the fluid flow path between the fluid transfer component interface and the cannula.
[0019] In some cases, the filter provides a physical filtration medium for removing unwanted material, such as by size exclusion.
[0020] In some cases, the filter provides a chemical filtration medium for removing unwanted substances, such as by sorption.
[0021] In some cases, the filter is a modular filter including a first sub-filter and a second sub-filter arranged to allow fluid to flow sequentially therethrough.
[0022] In some cases, the first subfilter includes a filter material and the second subfilter includes another filter material different from the filter material.
[0023] In some cases, the filter comprises foam. The foam may comprise any combination of cellulose, polyurethane (PU), polyester, polyether and collagen. Although foam is described herein, it is apparent that other structures such as films or sheets or the like may be used in place of the foam, and the properties described in relation to the foam are equally applicable to the film or sheet.
[0024] In some cases, the therapeutic agent comprises insulin, heparin, apomorphine, arbidopa (carbidopa), or levodopa and / or levodopa products.
[0025] In some cases, the cannula may include an inner cavity wall with a surface feature structure for holding and / or positioning the filter within the cannula. The cannula may be a soft polymer catheter or a metal needle. The cannula may include one of polytetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), rubber, polyethylene (PE), polyurethane (PU), polypropylene (PP), or silicone. The cannula may be inserted into the patient's body through an insertion needle.
[0026] The infusion devices with filters and related methods described herein can be used to inhibit FBR at the infusion site, thereby avoiding problems such as clotting, blockage and / or inflammation at the infusion site, and / or cystic effect of the cannula. Specifically, the devices and methods described herein can be used to inhibit FBR at the infusion site of a diabetic patient receiving CSII therapy. The infusion site can be a single infusion site used for a long period of time, such as at least four days.
[0027] The infusion devices with filters and related methods described herein can be used to remove unwanted substances from a therapeutic agent before the therapeutic agent is delivered to a patient, for example, unwanted substances include cytotoxic preservatives that must be present in an insulin solution to stabilize and / or sterilize the insulin solution before delivery to a patient. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Exemplary infusion devices and related methods are further described below with reference to the accompanying drawings, in which:
[0029] Figure 1A is a schematic diagram of the infusion set;
[0030] Figure 1B yes Figure 1A Further illustration of the infusion device shown;
[0031] Figure 2A is a side cross-sectional view of an exemplary infusion device;
[0032] Figure 2B yes Figure 2A A perspective view of an infusion device is shown;
[0033] Figure 2C yes Figure 2A A top cross-sectional view of the infusion device shown;
[0034] Figure 3A is a side cross-sectional view of another exemplary infusion device; and,
[0035] Figure 3B yes Figure 3A A top cross-sectional view of the infusion device is shown. DETAILED DESCRIPTION
[0036] Infusion device and related method described at present are particularly suitable for infusion pump system, for example, for delivering the infusion pump of therapeutic agent (such as insulin, heparin or any other liquid therapeutic agent), wherein infusion pump comprises fluid pump and reservoir, and has cannula (usually a part of infusion seat) and the infusion device of the pipeline that cannula is connected to reservoir.Infusion pump can be the insulin pump for CSII therapy, and therapeutic agent can be insulin preparation.Infusion device and related method described at present can deliver insulin to patient in single infusion position in the time of one section of extension.The time of one section of extension should be understood as at least four days.More specifically, the time of one section of extension can comprise 4 to 7 days, 7 days or more days, 7 to 10 days and 10 days or more days.The time of one section of extension can comprise 14 days or more days.
[0037] Figure 1A and Figure 1B An infusion device 1000 is shown positioned at an infusion site. The infusion device 1000 includes an infusion seat 35, which includes a main body 35a and a tubing connector 35b. The infusion seat 35 is fixed to the patient's skin by an adhesive patch 55, which holds the cannula 40 in the patient's subcutaneous fat tissue. The tubing 15 connects the pump outlet connector 30 of the pump 25 (the pump 25 containing the therapeutic agent) to the infusion seat 35 through the tubing connector 35b. The main body 35a includes a housing 70 and a fluid transmission component 50 that provides a fluid channel. The fluid transmission component is fixed in the housing 70 and holds the cannula 40 in the patient's body. The fluid transmission component 50 can be integral with the housing 70.
[0038] The pipe connector 35b engages with the interface 45 of the fluid transfer component 50 to connect the downstream end of the pipe 15 to the fluid transfer component 50. The pipe connector 35b comprises a releasable connector, in this case a releasable snap-fit fitting. Figure 1B As shown, the tubing connector 35b has a mechanical element in the form of an elastically deformable arm 21 that engages with a corresponding mechanical receiving element on the body 35a of the infusion adapter 35, or more specifically, with the housing 70 of the body 35a. Although the mechanical element is arranged as a releasable clamp in the tubing connector 35b shown, it is clear that this is not necessary. When the tubing connector 35b is fixed to the body 35a of the infusion adapter 35, the needle 75 of the tubing connector 35b pierces the sealing membrane 65 in the fluid transmission component 50, allowing the therapeutic agent to flow through the fluid transmission component 50 and enter the patient's body via the cannula 40.
[0039] The function of the fluid transfer component 50 is to allow fluid (such as a therapeutic agent) to be transferred through the infusion set 35 (i.e., from the interface 45 of the fluid transfer component 50 to the cannula 40). Figure 1A As can be seen in FIG. 5 , the fluid transport component 50 provides a fluid flow path that first extends generally parallel to the plane of the skin surface and then bends to be generally perpendicular to the skin surface.
[0040] The fluid transfer component 50 has a plurality of interfaces 45, 80. The sealing film 65 seals the first interface 45, and the second sealing film 85 is used to seal the second interface 80. Although two interfaces 45, 80 are shown, it is obvious that more than two interfaces can be provided as needed. Some or all interfaces may have a sealing film fixed therein to prevent the therapeutic agent from flowing out of the fluid transfer component 50 through the corresponding interface.
[0041] Cannula 40 is a generally tubular member for inserting and delivering a therapeutic agent to an infusion site 60. The therapeutic agent includes insulin or an insulin solution. The proximal end of cannula 40 is fluidly connected to a source of the therapeutic agent, here an infusion pump 25. The opposite distal end of cannula 40 is located in the infusion site 60 and extends to a desired depth to deliver the therapeutic agent. Cannula 40 is any suitable cannula suitable for implantation into a patient's tissue site, such as a polymer catheter or a metal needle.
[0042] FIG. 2A to FIG. 2C An exemplary infusion device 2000 is shown. FIG. 2A to FIG. 2C , similar components are denoted by the same reference numerals. The infusion set 2000 includes an infusion set 235, which includes a tube connector 200 for connecting to a main body 35a. As described above, the main body 35a includes a housing 70 and a fluid transfer component 50 fixed in the housing 70 and holding the cannula 40 in the patient's body. As described below, the tube connector 200 is different from the tube connector 35b.
[0043] The pipe connector 200 engages with the interface 45 of the fluid transfer component 50 to connect the downstream end of the pipe 15 to the fluid transfer component 50. The pipe connector 200 comprises a releasable connector, in this case a releasable snap-fit fitting. Figure 2B and Figure 2C As shown, the tubing connector 200 has a mechanical element in the form of an elastically deformable arm 210 that engages a corresponding mechanical receiving element on the body 35a of the infusion adapter 235, or more specifically, on the housing 70 of the body 35a. Although the mechanical element is arranged as a releasable clamp in the tubing connector 200 shown, it is clear that this is not necessary, and in some cases the mechanical element is not releasable. When the tubing connector 200 is fixed to the body 35a, the needle 215 of the tubing connector 200 pierces the sealing membrane 65 in the fluid transfer component 50, so that the therapeutic agent can flow through the fluid transfer component 50 and enter the patient's body via the cannula 40. The sealing membrane 65 prevents the therapeutic agent from leaking from the fluid transfer component 50.
[0044] The tubing connector 200 forms part of a fluid flow path between the pump 25 and the patient and includes a filter 205 for removing unwanted substances from the therapeutic agent before delivering the therapeutic agent to the patient near the end of the fluid flow path. The filter 205 is positioned in a cavity 220 between the inlet and outlet ends of the tubing connector 200 within the fluid flow path of the tubing connector 200. The cavity 220 has a geometry that substantially corresponds to the filter 205. The filter 225 can be cylindrical, conical, sheet-like, or in any functional form. In addition, the size of the filter 205 is at least adapted to the width of the cavity 220 so that any fluid (e.g., therapeutic agent) in the fluid flow path must pass through the filter 205. The tubing connector 200 has an upstream fluid lumen 225 that operably connects the tubing 15 to the cavity 220. At the other end of the cavity 220, a downstream fluid lumen 230 connects the cavity 220 to a needle 215 that penetrates the sealing membrane 65 of the fluid transmission component 50.
[0045] The pipe connector 200 is connected, preferably releasably connected, to the pipe 15. The pipe connector 200 may be connected to the pipe 15 by gluing or welding (e.g., ultrasonic welding) at the upstream end of the pipe connector 200. Those skilled in the art will appreciate that alternative methods of connecting the pipe connector 200 and the pipe 15 are possible.
[0046] Figure 3A and Figure 3B An exemplary infusion device 3000 is shown. FIG. 3A to FIG. 3B, similar components are denoted by the same reference numerals. The infusion set 3000 includes an infusion set 335, which includes a main body 335a and a pipe connector 35b. The main body 335a includes a housing 70 and a fluid transmission component 300 fixed in the housing 70. The fluid transmission component 300 holds the cannula 40 in the infusion set 335 and provides a fluid connection between the cannula 40 and the pipe 15 of the infusion set 3000. The fluid transmission component 300 may be integrally formed with the housing 70 of the main body 335a. Alternatively, the fluid transmission component 300 may be releasably connected to the housing 70 of the main body 335a.
[0047] The infusion seat 335 is fixed to the patient's skin by an adhesive patch 55, which holds the cannula 40 in the patient's subcutaneous fat tissue. The adhesive patch 55 extends across the entire underside of the body 335a of the infusion seat 335 to achieve good adhesion to the skin.
[0048] The pipeline 15 is connected to the main body 335a of the infusion seat 335 through the pipeline connector 35b, and the pipeline connector 35b is engaged with the interface 315 of the fluid transmission component 300. Figure 3B As shown, the tubing connector 35b has an elastically deformable arm 21 for releasably fixing the tubing connector 35b to the body 335a of the infusion adapter 335, more specifically, to the housing 70 of the body 335a, as described above. When the tubing connector 35b is fixed to the body 335a, the needle 75 of the tubing connector 35b pierces the sealing membrane 310 in the fluid transmission component 300, so that the therapeutic agent can flow through the fluid transmission component 300 and enter the patient's body via the cannula 40. The sealing membrane 310 prevents the therapeutic agent from flowing out of the fluid transmission component 300. The fluid transmission component 300 forms a part of the fluid flow path, so that the cannula 40 defines the downstream end of the fluid flow path extending between the pump outlet connector 30 and the patient via the fluid transmission component 300.
[0049] The fluid transfer component 300 also includes a filter 305 disposed in a cavity 320 in the fluid flow path, the cavity being defined between the interface 315 of the fluid transfer component 300 and the cannula 40. The cavity 320 has a geometry that substantially corresponds to the filter 305. The filter 325 may be cylindrical, conical, sheet-like, or any functional form of shape. In addition, the size of the filter 305 is adapted to at least the width of the cavity 320, so that any fluid (e.g., therapeutic agent) in the fluid flow path must pass through the filter 305. More specifically, the cavity 320 is a cylindrical space / vacancy in the fluid transfer component 300, positioned behind the sealing membrane 310 in the fluid flow path, and located at the end of the needle 75 of the tubing connector 35b connected from the tubing 15. Obviously, the cavity 320 may have any functional shape that corresponds to the filter. The needle 75 provides a fluid flow path through the tubing connector 35b, through the sealing membrane 310, and to the cavity 320.
[0050] The function of the fluid transfer component 300 is to allow fluid (eg, therapeutic agent) to be transferred through the infusion set 335 (ie, from the interface 315 of the fluid transfer component 300 to the cannula 40). Figure 3A As can be seen in FIG. 1 , the fluid transport component 300 provides a fluid flow path that first extends generally parallel to the plane of the skin surface and then bends to be generally perpendicular to the skin surface.
[0051] The fluid transfer component 300 has a plurality of interfaces 315, 325. The sealing film 310 seals the first interface 315, and the second sealing film 330 is used to seal the second interface 325. Although two interfaces 315, 325 are shown, it is obvious that more than two interfaces may be provided as needed. Some or all interfaces may have sealing films fixed therein to prevent the therapeutic agent from flowing out of the fluid transfer component 300 through the corresponding interface.
[0052] Positioning the filter 305 within the fluid transport component 300, proximate the cannula 40, allows the filter 305 to remove unwanted substances, such as preservatives, from the therapeutic agent at the point of delivery to the patient, i.e., near the end of the fluid flow path between the source of the therapeutic agent (infusion pump 25) and the infusion site 60. Thus, the therapeutic agent is stable throughout the infusion set.
[0053] Above-mentioned infusion set 2000,3000 all comprise filter 205,305.Filter is intended to remove the unwanted material present in therapeutic agent, for example, by filtering, to avoid FBR.Unwanted material used herein should be understood as one or more materials that may be present in therapeutic agent, for example, by design or accident, and may not wish to be retained in therapeutic agent when being delivered to infusion site.Specifically, filter can remove the unwanted material that occurs in insulin solution.This unwanted material can be particulate and / or molecule in nature.The example of unwanted particulate material comprises plastic particles, dust and insulin agglomerate, and they are produced in the process of manufacturing, storing, sterilizing or handling infusion set and / or insulin solution.The example of unwanted molecular species comprises the preservative that is commonly used in insulin solution, for example phenol, cresol (particularly metacresol), benzyl alcohol, benzalkonium chloride, cetrimide, chlorobutanol, chlorhexidine / chlorhexidine, chlorocresol, hydroxybenzoate, phenylethyl alcohol, phenoxyethanol and phenylmercuric nitrate.
[0054] The filter may include any filter material capable of removing one or more harmful substances from the therapeutic agent. To remove unwanted particulate matter, the filter material may provide a physical filter medium for removing unwanted substances by size exclusion, including whereby the filter material acts as a molecular sieve. Additionally or alternatively, to remove unwanted molecular substances, the filter material may provide a chemical filter medium for removing unwanted substances by sorption (e.g., by adsorption or ion exchange), whereby the filter material binds to the unwanted molecular substances to retain them within the filter. The filter material has a plurality of channels, such as pores (i.e., interconnected hollow voids), running therethrough to allow fluid to flow through the filter.
[0055] The filter can be a modular filter, including a first sub-filter and a second sub-filter, for allowing fluid to flow through in sequence to gradually remove different harmful substances from the therapeutic agent, such as harmful substances of different sizes and / or different molecular compositions. Therefore, the first sub-filter can include a different filter material than the second sub-filter. The filter can similarly include a third sub-filter, a fourth sub-filter, and so on.
[0056] Suitable filter materials include foams made of cellulose, polyurethane, polyester, polyether, collagen or the like. Although foams are described herein, it is apparent that other structures may be used, such as films or sheets or the like, to replace the foams, and the properties described in connection with the foams are equally applicable to the films or sheets. The foams include a plurality of channels in the form of interconnected pores running therethrough to allow fluid to flow through the filter. The foam may be any foam that can remove unwanted particulate matter from the insulin solution. The foam may remove unwanted particulate matter from the insulin solution by a size exclusion process.
[0057] Particularly suitable filter materials are disclosed in earlier patent applications including US 4,083,906 and US 1 1 197,949, the contents of which are incorporated herein by reference.
[0058] Suitable filter materials include ion exchange resins, including functionalized porous or gel polymers, which can remove unwanted substances from insulin solutions by gel permeation chromatography. In addition, gel polymers can be used to coat channels in filter materials.
[0059] Typically, a filter material can be selected having at least one material property that facilitates prolonged infusion of insulin at a single infusion site, thereby increasing the time of use, such as at least four days, including four to seven days, seven days or more days, seven to ten days, ten days or more days, and fourteen days or more days.
[0060] Advantageously, when the filter 205 is disposed within the tubing connector 200, the filter 205 is not limited by the size of the body 35a of the infusion adapter 35 (e.g., limited in area / e.g., within the size of the latter), and thus the body 35a of the infusion adapter 35 can be made smaller without affecting the functionality of the filter 205. This allows a wider range of filters and / or filter arrangements to be used (e.g., varying the size, number, etc. of the filters in a particular arrangement).
[0061] Advantageously, when the filter 205 is disposed in the tubing connector 200, the tubing connector 200 can be retrofitted to the infusion device 1000 (e.g., Figure 1A and Figure 1B ), thereby providing the advantages of the presently described infusion set 2000 without having to replace all components of the patient's existing infusion set 1000, thereby reducing waste.
[0062] Advantageously, when the filter 205 is disposed within the tubing connector 200, the tubing connector 200 and the infusion set 2000 described herein do not increase the number of components of the infusion set 1000, for example, Figure 1A and Figure 1B shown.
[0063] Advantageously, when the filter 305 is disposed within the cavity 320 of the fluid transport component 300, the overall size of the infusion set 35 and the visual appearance of the infusion set 3000 do not change beyond the infusion set 1000. Furthermore, the presently described infusion set 3000 does not increase the number of components of the infusion set 1000. Thus, a patient can benefit from the filter 305 of the infusion set 3000 while the infusion set 3000 is still portable for the patient.
[0064] Throughout the description and claims of this specification, the words "comprise" and "include" and their variations mean "including but not limited to", and they do not exclude other parts, additions, components, complete bodies or steps. Throughout the description and claims of this specification, the singular includes the plural, unless the context requires otherwise. In particular, where the indefinite article is used, the specification should be understood as contemplating plural as well as singular, unless the context requires otherwise.
[0065] Features, integers, characteristics or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All features disclosed in this specification (including any accompanying claims, abstract and drawings), and / or all steps of any method or process so disclosed, may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. The invention is not limited to the details of any foregoing embodiments. The invention extends to any novel one or any novel combination of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one or any novel combination of the steps of any method or process so disclosed.
Claims
1. An infusion seat for subcutaneously infusing a therapeutic agent into a patient, the infusion seat comprising: shell; a cannula for insertion into a patient; a fluid transfer component connected to the housing and in fluid communication with the cannula; and, a tubing connector configured to engage the fluid transfer component and connectable to tubing for receiving a therapeutic agent from the pump; wherein the cannula defines a downstream end of a fluid flow path extending between the pump and the patient via the fluid transfer component; and, Wherein, the infusion seat includes a filter arranged in the pipeline connector.
2. The infusion seat according to claim 1, wherein: The interface of the fluid transport component includes a sealing membrane configured to prevent fluid from flowing out of the fluid transport component from the fluid flow path.
3. The infusion seat according to claim 2, wherein: When the tubing connector is secured to the fluid transport component, the needle of the tubing connector pierces the sealing membrane of the fluid transport component.
4. The infusion seat according to any one of claims 1 to 3, wherein: The pipeline connector includes an upstream fluid inner cavity, a downstream fluid inner cavity, and a cavity disposed between the upstream fluid inner cavity and the downstream fluid inner cavity; Wherein, the filter is arranged in the cavity in the fluid flow path.
5. The infusion seat according to any one of claims 1 to 4, wherein: Filters provide a physical filtration medium for removing unwanted material by size exclusion.
6. The infusion seat according to any one of claims 1 to 5, wherein: Filters provide chemical filtration media for the removal of unwanted substances by sorption.
7. The infusion seat according to any one of claims 1 to 6, wherein: The filter is a modular filter including a first sub-filter and a second sub-filter, the first sub-filter and the second sub-filter being arranged to allow a fluid to flow therethrough sequentially.
8. The infusion seat according to claim 7, wherein: The first subfilter comprises a filter material and the second subfilter comprises another filter material different from the filter material.
9. The infusion seat according to any one of claims 1 to 8, wherein: The filter comprises a foam or a sheet or a film comprising cellulose, polyurethane (PU), polyester, polyether and / or collagen material.
10. An infusion device, comprising: The infusion seat according to any one of claims 1 to 9; and, A tube that can be connected between the tube connector of the infusion station and the pump.
11. The infusion device according to claim 10, further comprising a pump for containing the therapeutic agent and delivering the therapeutic agent to the infusion seat via the tube.
12. A method of treating a patient by subcutaneous infusion of a therapeutic agent, the method comprising the steps of: Placing the infusion seat according to any one of claims 1 to 9 at the infusion site of the patient, connecting a pump connected to a source of therapeutic agent fluid via a tube to the tube connector, priming the tube with a therapeutic agent, and The patient is injected with a therapeutic agent.
13. A method of treating a patient by subcutaneous infusion of a therapeutic agent, the method comprising the steps of: An infusion seat according to any one of claims 1 to 9 is provided, connecting a pump connected to a source of therapeutic agent fluid via a tube to the tube connector, Prime the tubes with therapeutic agents, Place the infusion set at the patient's infusion site, and The patient is injected with a therapeutic agent.
14. An infusion set for subcutaneously infusing a therapeutic agent into a patient, the infusion set comprising: shell; a cannula for insertion into a patient; a fluid transfer component connected to the housing and in fluid communication with the cannula; and, a tubing connector configured to engage the fluid transfer component and connectable to tubing for receiving a therapeutic agent from the pump; wherein the cannula defines a downstream end of a fluid flow path extending between the pump and the patient via the fluid transfer component; and, Wherein, the infusion seat includes a filter arranged in the fluid transmission component in the fluid flow path.
15. The infusion seat according to claim 14, wherein: The filter is disposed in the fluid flow path between the interface of the fluid transfer component and the cannula.
16. An infusion device, comprising: The infusion seat according to claim 14 or 15; and, A tube that can be connected between the tube connector of the infusion station and the pump.
17. The infusion device of claim 16, further comprising a pump for containing the therapeutic agent and delivering the therapeutic agent to the infusion seat via the tubing.
